FORMULATION AND INVITRO EVALUATION OF RAMIPRIL PULSATILE DRUG DELIVERY

Abstract

Ramipril as just a model drug, an ACE inhibitor used to treat hypertension and lower cardiovascular mortality after myocardial injury in cardiac stable patients with congestive heart failure, the current study set out to design and evaluate an oral, site-specific, pulsatile drug delivery system. A insoluble hard gelatin capsules body, a powder mixture, and a hydrogel plug serve as the foundation of the fundamental design. Ramipril, Ludiflash, Lycoat, MCC, and Talc powder was made and tested for flow characteristics and FTIR investigations. Based on the results, the F4 powder mix formulation was chosen for use in the subsequent production of pulsatile capsules. Hydrogel plug was created using both hydrophobic polymer alone and in combination. In order to maintain a proper lag period, hydrophilic polymer like HPMC K15M were combined with hydrophobic polymers such ethyl cellulose in ratios of 1:1, 1:2, and 2:1. It was discovered that drug release was regulated by the ratio of polymers utilised. The produced formulations' drug content, weight fluctuation, and in vitro release tests were all assessed. Ramipril was released from pulsincap after a preset lag time of 9 hours, according to research on the in vitro release of the pulsatile device. FTIR investigations verified that there was not an interaction between the medication and polymers. Based on in vitro research, P5F4 was determined to be the best formulation.